Resveratrol inhibits ovarian tumor growth in an in vivo mouse model. (Q51569550)

7 April 2018

title

Resveratrol inhibits ovarian tumor growth in an in vivo mouse model. (English)

1 reference

7 April 2018

author name string

Lijun Tan

1

1 reference

7 April 2018

Weimin Wang

2

1 reference

7 April 2018

Gong He

3

1 reference

7 April 2018

Rork D Kuick

4

1 reference

7 April 2018

Gabrielle Gossner

5

1 reference

7 April 2018

Angela S Kueck

6

1 reference

7 April 2018

Heather Wahl

7

1 reference

7 April 2018

Anthony W Opipari

8

1 reference

7 April 2018

J Rebecca Liu

9

1 reference

7 April 2018

language of work or name

English

0 references

publication date

30 November 2015

1 reference

7 April 2018

published in

Cancer

1 reference

7 April 2018

volume

122

1 reference

7 April 2018

issue

5

1 reference

7 April 2018

page(s)

722-729

1 reference

7 April 2018

Targeting cellular metabolism to improve cancer therapeutics

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29793

Resveratrol inhibits glucose metabolism in human ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29793

The lifespan extension effects of resveratrol are conserved in the honey bee and may be driven by a mechanism related to caloric restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29793

Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29793

Metabolic roles of AMPK and metformin in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29793

Glucose deprivation activates AMPK and induces cell death through modulation of Akt in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29793

In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29793

Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29793

Resveratrol suppresses cancer cell glucose uptake by targeting reactive oxygen species-mediated hypoxia-inducible factor-1α activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29793

Resveratrol in metabolic health: an overview of the current evidence and perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29793

Cancer-specific interruption of glucose metabolism by resveratrol is mediated through inhibition of Akt/GLUT1 axis in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29793

Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29793

Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29793

Targeting cancer metabolism: a therapeutic window opens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29793

Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29793

21 January 2018

Identifiers

DOI

10.1002/CNCR.29793

1 reference

7 April 2018

PubMed ID

26619367

1 reference

7 April 2018